Who
Owen N. Witte
Director
Company insider
Files Form 4 as: Director, Allogene Therapeutics; Director, Kite Pharma.
In numbers
- Trades disclosed
- 39
- Buys
- 1
- Sells
- 10
- Bought
- $270K
- Sold
- $3.7M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 14 Mar 2017
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —191,082 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —74,561 at $0.00 | filing |
| 12 Aug 2022filed 15 Aug 2022 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $86K5,000 at $17.25 | filing |
| 12 Aug 2022filed 15 Aug 2022 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $86K5,000 at $17.25 | filing |
| 11 Aug 2022filed 15 Aug 2022 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $165K10,000 at $16.50 | filing |
| 11 Aug 2022filed 15 Aug 2022 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $165K10,000 at $16.50 | filing |
| 22 Jun 2022filed 23 Jun 2022 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $118K10,000 at $11.76 | filing |
| 15 Jun 2022filed 17 Jun 2022 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,535 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —22,089 at $0.00 | filing |
| 9 Sep 2021filed 9 Sep 2021 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $128K5,000 at $25.54 | filing |
| 20 Aug 2021filed 23 Aug 2021 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $119K5,000 at $23.70 | filing |
| 20 Aug 2021filed 23 Aug 2021 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $116K5,000 at $23.24 | filing |
| 10 Jun 2021filed 11 Jun 2021 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,015 at $0.00 | filing |
| 9 Jun 2021filed 11 Jun 2021 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $250K9,969 at $25.05 | filing |
| 5 Jun 2020filed 9 Jun 2020 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —9,969 at $0.00 | filing |
| 6 Jun 2019filed 24 Jun 2019 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,025 at $0.00 | filing |
| 15 Oct 2018filed 17 Oct 2018 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Bought | $270K15,000 at $18.00 | filing |
News
Head to Head Analysis: Keros Therapeutics (NASDAQ:KROS) & Allogene Therapeutics (NASDAQ:ALLO)ALLO · tickerreport.com · 24 Oct 2026Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026
0 headlines in the last 90 days name Owen N. Witte; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.